新入荷 再入荷

The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey | Annals of Hematology

flash sale icon タイムセール
終了まで
00
00
00
999円以上お買上げで送料無料(
999円以上お買上げで代引き手数料無料
通販と店舗では販売価格や税表示が異なる場合がございます。また店頭ではすでに品切れの場合もございます。予めご了承ください。
新品 6300円 (税込)
数量

The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey | Annals of Hematology

The burden of illness in patients with paroxysmal nocturnal hemoglobinuria  receiving treatment with the C5-inhibitors eculizumab or ravulizumab:  results from a US patient survey | Annals of HematologyThe burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey | Annals of Hematology,36KB36KB,Prediction of the Number of Patients Infected with COVID-19 Based on  Rolling Grey Verhulst ModelsPrediction of the Number of Patients Infected with COVID-19 Based on Rolling Grey Verhulst Models,57KB57KB,Nano-biochar as a potential amendment for metal(loid) remediation:  Implications for soil quality improvement and stress alleviation -  ScienceDirectNano-biochar as a potential amendment for metal(loid) remediation: Implications for soil quality improvement and stress alleviation - ScienceDirect

 

商品情報の訂正

このページに記載された商品情報に記載漏れや誤りなどお気づきの点がある場合は、下記訂正依頼フォームよりお願い致します。

訂正依頼フォーム

商品レビュー

レビューの投稿にはサインインが必要です